Dopamine D4 receptor stimulation prevents nigrostriatal dopamine pathway activation by morphine: relevance for drug addiction

Addict Biol. 2017 Sep;22(5):1232-1245. doi: 10.1111/adb.12407. Epub 2016 May 22.

Abstract

Morphine is one of the most effective drugs used for pain management, but it is also highly addictive. Morphine elicits acute and long-term adaptive changes at cellular and molecular level in the brain, which play a critical role in the development of tolerance, dependence and addiction. Previous studies indicated that the dopamine D4 receptor (D4 R) activation counteracts morphine-induced adaptive changes of the μ opioid receptor (MOR) signaling in the striosomes of the caudate putamen (CPu), as well as the induction of several Fos family transcription factors. Thus, it has been suggested that D4 R could play an important role avoiding some of the addictive effects of morphine. Here, using different drugs administration paradigms, it is determined that the D4 R agonist PD168,077 prevents morphine-induced activation of the nigrostriatal dopamine pathway and morphological changes of substantia nigra pars compacta (SNc) dopamine neurons, leading to a restoration of dopamine levels and metabolism in the CPu. Results from receptor autoradiography indicate that D4 R activation modulates MOR function in the substantia nigra pars reticulata (SNr) and the striosomes of the CPu, suggesting that these regions are critically involved in the modulation of SNc dopamine neuronal function through a functional D4 R/MOR interaction. In addition, D4 R activation counteracts the rewarding effects of morphine, as well as the development of hyperlocomotion and physical dependence without any effect on its analgesic properties. These results provide a novel role of D4 R agonist as a pharmacological strategy to prevent the adverse effects of morphine in the treatment of pain.

Keywords: caudate putamen; dopamine D4 receptor; morphine.

MeSH terms

  • Analgesics, Opioid / pharmacology*
  • Animals
  • Autoradiography
  • Benzamides / pharmacology*
  • Caudate Nucleus / drug effects
  • Caudate Nucleus / metabolism
  • Dopamine Agonists / pharmacology*
  • Drug Tolerance
  • Male
  • Morphine / pharmacology*
  • Neostriatum / drug effects*
  • Neostriatum / metabolism
  • Pars Compacta / drug effects
  • Pars Compacta / metabolism
  • Pars Reticulata / drug effects
  • Pars Reticulata / metabolism
  • Piperazines / pharmacology*
  • Putamen / drug effects
  • Putamen / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Dopamine D4 / agonists*
  • Receptors, Dopamine D4 / metabolism
  • Receptors, Opioid, mu / metabolism
  • Reward*
  • Substance-Related Disorders / metabolism
  • Substantia Nigra / drug effects*
  • Substantia Nigra / metabolism

Substances

  • Analgesics, Opioid
  • Benzamides
  • Dopamine Agonists
  • Drd4 protein, rat
  • N-((4-(2-cyanophenyl)-1-piperazinyl)methyl)-3-methylbenzamide
  • Piperazines
  • Receptors, Opioid, mu
  • Receptors, Dopamine D4
  • Morphine